NO20054855L - Preventiv/hjelpemiddel for retinal nervesykdommer inneholdende alkyleterderivater eller salter derav - Google Patents

Preventiv/hjelpemiddel for retinal nervesykdommer inneholdende alkyleterderivater eller salter derav

Info

Publication number
NO20054855L
NO20054855L NO20054855A NO20054855A NO20054855L NO 20054855 L NO20054855 L NO 20054855L NO 20054855 A NO20054855 A NO 20054855A NO 20054855 A NO20054855 A NO 20054855A NO 20054855 L NO20054855 L NO 20054855L
Authority
NO
Norway
Prior art keywords
alkyl ether
retinal
retinal nerve
contraceptive
remedy
Prior art date
Application number
NO20054855A
Other languages
English (en)
Other versions
NO20054855D0 (no
NO334062B1 (no
Inventor
Akihito Saitoh
Noboru Iwakami
Tatsuo Kimura
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of NO20054855D0 publication Critical patent/NO20054855D0/no
Publication of NO20054855L publication Critical patent/NO20054855L/no
Publication of NO334062B1 publication Critical patent/NO334062B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et alkyleterderivat representert ved den generelle formel [1] eller dens salt: hvor R1 og R2 hver representerer en substituent så som hydrogen, halogen eller alkyl; R3 representerer alkylamino, amino eller hydroksyl; ringen A representerer en 5- eller 6-leddet aromatisk heterosyklisk gruppe eller en benzenring; m og n er hver et helt tall på fra 1 til 6; og p er et helt tall på fra 1 til 3; viser en effekt ved å beskytte retinale nerveceller og er derfor anvendelige som et forebyggende og/eller behandlende middel for retinale nervesykdommer så som glaukom, diabetisk retinopati, retinal arterie-obstruksjon, retinal venøs obstruksjon, makuladegenerasjon og retinopati ved prematuritet.
NO20054855A 2003-04-17 2005-10-20 Alkyleterderivater eller salter derav for behandling og/eller forebygging av retinale nervesykdommer NO334062B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003112539 2003-04-17
PCT/JP2004/005355 WO2004091605A1 (ja) 2003-04-17 2004-04-15 アルキルエーテル誘導体またはその塩を含有する網膜神経疾患の予防・治療剤

Publications (3)

Publication Number Publication Date
NO20054855D0 NO20054855D0 (no) 2005-10-20
NO20054855L true NO20054855L (no) 2006-01-09
NO334062B1 NO334062B1 (no) 2013-12-02

Family

ID=33296058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054855A NO334062B1 (no) 2003-04-17 2005-10-20 Alkyleterderivater eller salter derav for behandling og/eller forebygging av retinale nervesykdommer

Country Status (20)

Country Link
US (3) US20060205709A1 (no)
EP (1) EP1614419B1 (no)
JP (1) JP4642657B2 (no)
KR (1) KR101096528B1 (no)
CN (1) CN100353942C (no)
AU (1) AU2004229283B2 (no)
BR (1) BRPI0409398A (no)
CA (1) CA2521648C (no)
CY (1) CY1113248T1 (no)
DK (1) DK1614419T3 (no)
ES (1) ES2391273T3 (no)
IL (1) IL171388A (no)
MX (1) MXPA05011125A (no)
NO (1) NO334062B1 (no)
NZ (1) NZ543100A (no)
PL (1) PL1614419T3 (no)
PT (1) PT1614419E (no)
SI (1) SI1614419T1 (no)
WO (1) WO2004091605A1 (no)
ZA (1) ZA200508166B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0213393B8 (pt) * 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
PT2348022E (pt) * 2005-03-28 2013-02-13 Toyama Chemical Co Ltd Processo para a produção de 1-(3-(2-(1- benzotiofen-5-il)etoxi)propil)azetidin-3-ol ou dos seus sais
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
SI2011796T1 (sl) * 2006-04-26 2015-02-27 Toyama Chemical Co., Ltd. Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega
JP5255441B2 (ja) * 2006-08-04 2013-08-07 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有するプロテインキナーゼｃ活性促進剤
PT2300514E (pt) 2008-07-14 2016-06-20 Biocon Ltd Um método de síntese de uma mistura substancialmente monodispersa de oligómeros
CN104159583B (zh) * 2012-02-22 2018-04-13 富山化学工业株式会社 含有1‑(3‑(2‑(1‑苯并噻吩‑5‑基)乙氧基)丙基)氮杂环丁烷‑3‑醇或其盐的固体药物组合物
LT3100725T (lt) * 2014-01-31 2020-08-10 Fujifilm Toyama Chemical Co., Ltd. Reabilitacijos poveikį po nervo pažeidimo sustiprinanti priemonė, apimanti alkileterio darinį arba jo druską
EP3308782B1 (en) * 2015-06-11 2022-01-19 Toyama Chemical Co., Ltd. Sigma-receptor binding agent
KR102703879B1 (ko) 2015-12-25 2024-09-05 후지필름 도야마 케미컬 가부시키가이샤 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 포함하는 정제
JP7176957B2 (ja) 2016-12-28 2022-11-22 富士フイルム富山化学株式会社 外用組成物
WO2018221732A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アミロイドβ蛋白質量減少剤
NZ759585A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
NZ759647A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating spinocerebellar ataxia
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521136A1 (fr) * 1982-02-05 1983-08-12 Synthelabo Derives de piperidine, leur preparation et leur application en therapeutique
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
DK74693D0 (da) 1993-06-23 1993-06-23 Novo Nordisk As Novel heterocyclic chemistry
TW281667B (no) * 1994-02-03 1996-07-21 Synthelabo
EP0873990A1 (en) 1995-09-22 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and medicinal use thereof
JP4549452B2 (ja) * 1997-12-12 2010-09-22 富山化学工業株式会社 アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
AU9235101A (en) * 2000-10-10 2002-04-22 Toyama Chemical Co Ltd Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
BRPI0213393B8 (pt) * 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
SI2389937T1 (sl) * 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije

Also Published As

Publication number Publication date
NZ543100A (en) 2008-07-31
PT1614419E (pt) 2012-10-22
ES2391273T3 (es) 2012-11-23
AU2004229283B2 (en) 2009-02-05
US7897594B2 (en) 2011-03-01
WO2004091605A1 (ja) 2004-10-28
US20110112066A1 (en) 2011-05-12
NO20054855D0 (no) 2005-10-20
AU2004229283A1 (en) 2004-10-28
JP4642657B2 (ja) 2011-03-02
CN1774245A (zh) 2006-05-17
KR101096528B1 (ko) 2011-12-20
DK1614419T3 (da) 2012-11-19
EP1614419A4 (en) 2010-08-18
IL171388A (en) 2010-12-30
US8067406B2 (en) 2011-11-29
KR20050123167A (ko) 2005-12-29
BRPI0409398A (pt) 2006-04-18
CA2521648C (en) 2012-07-03
US20060205709A1 (en) 2006-09-14
EP1614419B1 (en) 2012-08-08
JPWO2004091605A1 (ja) 2006-07-06
EP1614419A1 (en) 2006-01-11
ZA200508166B (en) 2007-03-28
CN100353942C (zh) 2007-12-12
PL1614419T3 (pl) 2013-01-31
SI1614419T1 (sl) 2012-12-31
NO334062B1 (no) 2013-12-02
CY1113248T1 (el) 2016-04-13
US20100075941A1 (en) 2010-03-25
MXPA05011125A (es) 2005-12-14
CA2521648A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
NO20054855L (no) Preventiv/hjelpemiddel for retinal nervesykdommer inneholdende alkyleterderivater eller salter derav
CA3000483C (en) Compounds, compositions, and methods for modulating cftr
NO20062370L (no) Amidderivater
NO20073730L (no) Amidderivater
TW200617001A (en) Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same
NO20041531L (no) Alkyleterderivater eller salter derav
NO20053133L (no) Kjemiske forbindelser.
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
NO20063382L (no) Nye kinolinderivater
NO20052038L (no) Ny adeninforbindelse og anvendelse derav
NO20083542L (no) Nye kumarinderivater med antitumoraktivitet
MX2009006024A (es) Derivados de heteroaril piridopirimidona sustituidos.
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
BRPI0408189A (pt) 8'-piridinil-dihidroespiro-[cicloalquil]-pirimido[1,2-a]p irimidin-6-ona substituìda e derivados de 8'-pirimidinil-dihidroespiro-[cicloalquil]-pirimido[1,2- a]pirimidin-6-ona e seus usos contra doenças neurodegenerativas
NO20072389L (no) Substituerte benzokinolizinderivater
WO2004031160A3 (fr) Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
NO20045483L (no) Bedring av utviklingen av katarakt og andre oftalmiske sykdommer
JPWO2004092179A1 (ja) スピロ誘導体、製造法および抗酸化薬
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter
EA200901402A1 (ru) Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
WO2009041566A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
NO312296B1 (no) Benzoksazinon-dopamin-D4-reseptor-antagonister, anvendelse derav, samt farmasöytisk preparat
CA3124838A1 (en) Methods and formulations to treat mitochondrial dysfunction

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees